BioXcel Therapeutics
BTAI
BTAI was delisted on the 4th of September, 2026.
22 hedge funds and large institutions have $47.9M invested in BioXcel Therapeutics in 2018 Q1 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.88% more ownership
Funds ownership: 0% → 1.88% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.4M |
| 2 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$12.6M |
| 3 |
Barclays
London,
United Kingdom
|
+$6.45M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$3.43M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.08M |
Top Sellers
BTAI Hedge Fund Activity: Q1 2018 in Review
22 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2018, worth a combined $47.9M.
Buyers outnumbered sellers: 22 funds opened new BTAI positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $17.4M.
- 22 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $47.9M of BioXcel Therapeutics stock for Q1 2018.
- 22 funds opened new BioXcel Therapeutics positions in Q1 2018 and 0 closed out, a net change of +22 holders.
- The largest BioXcel Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $17.4M added.
Based on aggregated 13F filings for Q1 2018.